Invest in Breethwell: Pioneering Respiratory Wellness

 

Breethwell is poised to transform lives by addressing a silent epidemic: Day Apnea, the subconscious breath-holding or shallow breathing disrupting millions daily. Our patented CMAP (Continuously Monitoring Airway Pressure) device is a wearable IoT breakthrough that monitors and corrects irregular breathing in real-time, with a market launch planned for early 2026. By targeting wellness, breathwork, clinical research, therapy, fitness, and more, Breethwell invites visionary investors to join a high-growth venture tapping a multi-billion-dollar opportunity.

​

 

Why Breethwell?

​

Founded on over 20 years of research through the Pacific Neuroscience Institute, Breethwell emerged from a discovery: daytime breathing irregularities, like Day Apnea and Screen Apnea, drive health risks, including hypertension, anxiety, and fatigue. Impacting 25 million Americans with tinnitus, 13 million with PTSD, and 19.1 million with anxiety, this epidemic is unaddressed by traditional tools. CMAP, using a precise nasal/oral cannula, outperforms bulky chest-band monitors (e.g., CapnoTrainer, $2,950). Early tests revealed nearly all users exhibit breath-holding, with promising reductions in blood pressure and anxiety, positioning CMAP as a leader across multiple verticals.

 

​

CMAP: A Versatile Platform

​

CMAP, a compact (2” x 2.5” x 0.75”) device, tracks airflow, heart rate, and blood oxygen (SpO₂), connecting via Bluetooth to a smartphone app for real-time alerts and guided exercises. Unlike sleep-focused therapies and machines, CMAP targets daytime breathing, serving diverse applications:

 

Wellness & Breathwork: Integrates with platforms like Headspace and Breathwrk, supporting meditation and pranayama, a booming sector (Global Wellness Summit, 2021).

 

Clinical Research: High-resolution data aids studies on Day Apnea’s role in PTSD, hypertension, and more.

 

Therapy: Targets FDA approval for hypertension and anxiety, following Resperate’s success (35,000 units sold, 2023).

 

Fitness & Performance: Enhances athletic training by optimizing breathing, appealing to sports markets.

 

Pain Management: Supports therapeutic breathing for chronic pain and stress relief. With U.S. and international patents pending, CMAP’s affordability ($299 - $499) and third-party wearable compatibility drive broad adoption.

 

​

Market Opportunity

​

The $9 billion sleep apnea market ignores daytime breathing, creating a unique niche. With 62% of Americans spending 4+ hours on screens daily (Common Sense Media, 2024), Screen Apnea affects millions, as shown by a 2007 Microsoft study (40% hold breath while emailing). Breethwell’s revenue model, direct-to-consumer sales, corporate deals (e.g., tech firms, VA), in-app purchases (breathwork exercises, analytics), and licensing to fitness and wellness platforms, targets a $7.3 billion CPAP market by 2034. Consumables (cannulas, SpO₂ sensors) and breathwork cross-promotions add recurring income.

 

 

Investment Potential

​

Breethwell seeks investment to fund CMAP’s manufacturing, pilot studies, FDA 510(k) clearances and 2026 launch. Funds will drive marketing to wellness, fitness, and healthcare sectors, with a focus on corporate partnerships. Backed by proven research, patented technology, and a wellness trend surge, Breethwell offers a high-return opportunity. Early data and breathwork integrations signal strong market fit.

 

​

Join the Breathing Revolution

​

Investing in Breethwell means championing a future where millions breathe better, perform better, and live healthier. Contact us at invest@breethwell.com to explore this transformative opportunity.